HRP20150439T1 - Protutijela za humani angiopoietin 2 - Google Patents
Protutijela za humani angiopoietin 2 Download PDFInfo
- Publication number
- HRP20150439T1 HRP20150439T1 HRP20150439TT HRP20150439T HRP20150439T1 HR P20150439 T1 HRP20150439 T1 HR P20150439T1 HR P20150439T T HRP20150439T T HR P20150439TT HR P20150439 T HRP20150439 T HR P20150439T HR P20150439 T1 HRP20150439 T1 HR P20150439T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- seq
- antibody fragment
- variable domain
- ang
- Prior art date
Links
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 title claims 4
- 102000047825 human ANGPT2 Human genes 0.000 title claims 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 19
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 19
- 102000009075 Angiopoietin-2 Human genes 0.000 claims 3
- 108010048036 Angiopoietin-2 Proteins 0.000 claims 3
- 238000000034 method Methods 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000009088 Angiopoietin-1 Human genes 0.000 claims 1
- 108010048154 Angiopoietin-1 Proteins 0.000 claims 1
- 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 102000044072 human ANGPT1 Human genes 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Claims (13)
1. Protutijelo ili fragment protutijela, koje se specifično veže za humani angiopoietin 2 (ANG-2), naznačeno time, da
a) varijabilna domena jakog lanca sadrži područje CDR3 od SEQ ID NO:1, područje CDR2 od SEQ ID NO:2 i područje CDR1 od SEQ ID NO:3, i
b) varijabilna domena slabog lanca sadrži područje CDR3 od SEQ ID NO:4, područje CDR2 od SEQ ID NO:5 i područje CDR1 od SEQ ID NO:6.
2. Protutijelo ili fragment protutijela, prema zahtjevu 1, naznačeno time, da obuhvaća
a) varijabilnu domenu jakog lanca od SEQ ID NO:7, i
b) varijabilnu domenu slabog lanca od SEQ ID NO:8.
3. Protutijelo ili fragment protutijela, prema zahtjevu 1 ili zahtjevu 2, naznačeno time, da se protutijelo ne veže na humani angiopoietin 1 (ANG-1).
4. Protutijelo ili fragment protutijela, prema bilo kojem od zahtjeva 1 do 3, naznačeno time, da je navedeno protutijelo iz humanog podrazreda IgG4 ili je iz humanog podrazreda IgG1.
5. Farmaceutski sastav, naznačen time, da obuhvaća protutijelo ili fragment protutijela prema bilo kojem od zahtjeva 1 do 4.
6. Protutijelo ili fragment protutijela, prema bilo kojem od zahtjeva 1 do 4, naznačeno time, da se upotrebljava za liječenje.
7. Protutijelo ili fragment protutijela, prema bilo kojem od zahtjeva 1 do 4, naznačeno time, da se upotrebljava u postupku za sprečavanje metastaza.
8. Protutijelo ili fragment protutijela, prema bilo kojem od zahtjeva 1 do 4, naznačeno time, da se upotrebljava u postupku liječenja raka.
9. Protutijelo ili fragment protutijela, prema bilo kojem od zahtjeva 1 do 4, naznačeno time, da se upotrebljava u postupku liječenja vaskularnih bolesti.
10. Protutijelo ili fragment protutijela, prema bilo kojem od zahtjeva 1 do 4, naznačeno time, da se upotrebljava u postupku liječenja retinopatije.
11. Nukleinska kiselina koja kodira jaki lanac i slabi lanac protutijela koje se specifično veže na humani angiopoietin 2 (ANG-2), naznačena time, da navedeno protutijelo obuhvaća varijabilnu domenu jakog lanca i varijabilnu domenu slabog lanca, prema zahtjevu 1.
12. Vektor ekspresije, naznačen time, da obuhvaća nukleinsku kiselinu prema zahtjevu 11, za ekspresiju protutijela koje se specifično veže na humani angiopoietin 2 (ANG-2) u prokariotskoj ili eukariotskoj stanici domaćina.
13. Prokariotska ili eukariotska stanica domaćina, naznačena time, da obuhvaća vektor prema zahtjevu 12.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08021835 | 2008-12-16 | ||
| PCT/EP2009/008930 WO2010069532A1 (en) | 2008-12-16 | 2009-12-14 | Antibodies against human angiopoietin 2 |
| EP09793471.5A EP2379592B1 (en) | 2008-12-16 | 2009-12-14 | Antibodies against human angiopoietin 2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20150439T1 true HRP20150439T1 (hr) | 2015-05-22 |
Family
ID=40585738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20150439TT HRP20150439T1 (hr) | 2008-12-16 | 2015-04-22 | Protutijela za humani angiopoietin 2 |
Country Status (34)
| Country | Link |
|---|---|
| US (12) | US8133979B2 (hr) |
| EP (1) | EP2379592B1 (hr) |
| JP (2) | JP5559191B2 (hr) |
| KR (2) | KR101445518B1 (hr) |
| CN (3) | CN102257008A (hr) |
| AR (2) | AR074756A1 (hr) |
| AU (1) | AU2009328613B2 (hr) |
| BR (1) | BRPI0923434A2 (hr) |
| CA (2) | CA2744624C (hr) |
| CL (2) | CL2011001285A1 (hr) |
| CR (2) | CR20110321A (hr) |
| CY (1) | CY1116264T1 (hr) |
| DK (1) | DK2379592T3 (hr) |
| EC (2) | ECSP11011139A (hr) |
| ES (1) | ES2534635T3 (hr) |
| HK (2) | HK1172349A1 (hr) |
| HR (1) | HRP20150439T1 (hr) |
| HU (1) | HUE024545T2 (hr) |
| IL (2) | IL213039A (hr) |
| MA (1) | MA32876B1 (hr) |
| MX (1) | MX2011005908A (hr) |
| MY (2) | MY155654A (hr) |
| NZ (2) | NZ600005A (hr) |
| PE (2) | PE20120551A1 (hr) |
| PH (1) | PH12013502192A1 (hr) |
| PL (1) | PL2379592T3 (hr) |
| PT (1) | PT2379592E (hr) |
| RU (2) | RU2569107C2 (hr) |
| SG (1) | SG172216A1 (hr) |
| SI (1) | SI2379592T1 (hr) |
| TW (2) | TWI482631B (hr) |
| UA (2) | UA103912C2 (hr) |
| WO (1) | WO2010069532A1 (hr) |
| ZA (2) | ZA201103990B (hr) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8557243B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | EFGR antibodies comprising modular recognition domains |
| US8557242B2 (en) | 2008-01-03 | 2013-10-15 | The Scripps Research Institute | ERBB2 antibodies comprising modular recognition domains |
| NZ586701A (en) | 2008-01-03 | 2013-07-26 | Scripps Research Inst | Antibody targeting through a modular recognition domain (MRD) wherein the MRD targets angiopoietin-2 (ANG-2) |
| US8454960B2 (en) | 2008-01-03 | 2013-06-04 | The Scripps Research Institute | Multispecific antibody targeting and multivalency through modular recognition domains |
| US8574577B2 (en) | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| US8133979B2 (en) * | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| CN102369215B (zh) | 2009-04-02 | 2015-01-21 | 罗切格利卡特公司 | 包含全长抗体和单链Fab片段的多特异性抗体 |
| US20120189635A1 (en) | 2009-07-29 | 2012-07-26 | Regeneron Pharmaceuticals, Inc. | Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2) |
| US8980268B2 (en) | 2009-07-29 | 2015-03-17 | Regeneron Pharamceuticals, Inc. | Methods for treating cancer by administering an anti-Ang-2 antibody |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US20120302737A1 (en) | 2009-09-16 | 2012-11-29 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
| BR112013001847A2 (pt) | 2010-08-24 | 2016-05-31 | Hoffmann La Roche | anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica |
| SG191153A1 (en) | 2010-12-23 | 2013-07-31 | Hoffmann La Roche | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| CN102221615A (zh) * | 2011-03-31 | 2011-10-19 | 广州华灿医药科技有限公司 | 一种基于Angiogenin检测的双抗夹心ELISA方法 |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| US9512220B2 (en) | 2011-04-05 | 2016-12-06 | Neopharm Co., Ltd. | Antibodies against angiopoietins 1 and 2, and their use |
| CN103857699B (zh) | 2011-05-24 | 2016-08-31 | 泽恩格尼亚股份有限公司 | 多价和单价多特异性复合物及其用途 |
| ES2757473T3 (es) | 2011-09-30 | 2020-04-29 | Dana Farber Cancer Inst Inc | Péptidos terapéuticos que comprenden anticuerpos que se unen a la secuencia A relacionada con el polipéptido del CMH de clase I (MICA) |
| JP6486686B2 (ja) | 2012-02-10 | 2019-03-20 | ジェネンテック， インコーポレイテッド | 単鎖抗体及び他のヘテロ多量体 |
| JP2015520168A (ja) * | 2012-05-24 | 2015-07-16 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 多重特異性抗体 |
| WO2014001325A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
| RU2639287C2 (ru) | 2012-06-27 | 2017-12-20 | Ф. Хоффманн-Ля Рош Аг | Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения |
| EP3495387B1 (en) | 2012-07-13 | 2021-09-01 | Roche Glycart AG | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
| KR101967345B1 (ko) | 2012-10-18 | 2019-04-09 | 삼성전자주식회사 | 안지오포이에틴-2와 인테그린 간의 결합을 저해하는 펩타이드 및 그 용도 |
| WO2014108854A1 (en) * | 2013-01-09 | 2014-07-17 | Fusimab Ltd. | Monospecific anti-hgf and anti-ang2 antibodies and bispecific anti-hgf/anti-ang2 antibodies |
| EP3424530A1 (en) | 2013-03-15 | 2019-01-09 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| WO2014151834A2 (en) | 2013-03-15 | 2014-09-25 | Amgen Inc. | Methods and compositions relating to anti-ccr7 antigen binding proteins |
| SG11201506766PA (en) | 2013-03-15 | 2015-09-29 | Dana Farber Cancer Inst Inc | Therapeutic peptides |
| KR102131371B1 (ko) | 2013-07-02 | 2020-07-08 | 삼성전자주식회사 | Ang-2 특이적 항체 및 그의 용도 |
| EP3381940B1 (en) | 2013-07-29 | 2022-09-07 | Samsung Electronics Co., Ltd. | Anti-ang2 antibody |
| KR102146845B1 (ko) | 2013-07-30 | 2020-08-21 | 삼성전자주식회사 | 앤지오포이에틴-2에 특이적으로 결합하는 항체 및 그의 용도 |
| KR102196450B1 (ko) | 2013-09-17 | 2020-12-30 | 삼성전자주식회사 | Tie2와 결합을 유도하는 항 Ang2 항체를 포함하는 항암제 |
| CN105611944A (zh) * | 2013-12-20 | 2016-05-25 | 豪夫迈·罗氏有限公司 | 抗ang2抗体和cd40激动剂的组合疗法 |
| KR102206029B1 (ko) | 2014-01-27 | 2021-01-20 | 삼성전자주식회사 | Ang-2에 특이적으로 결합하는 항체 및 그의 용도 |
| EP3116903A2 (en) | 2014-03-14 | 2017-01-18 | Dana-Farber Cancer Institute, Inc. | Vaccine compositions and methods for restoring nkg2d pathway function against cancers |
| US9957333B2 (en) * | 2014-04-17 | 2018-05-01 | Case Western Reserve University | Anti-CEP antibody or fragment thereof |
| AR100270A1 (es) * | 2014-05-19 | 2016-09-21 | Lilly Co Eli | Anticuerpos ang2 |
| KR102349370B1 (ko) | 2014-05-26 | 2022-01-10 | 삼성전자주식회사 | 인간화 또는 친화도 성숙된 항 앤지오포이에틴-2 항체 및 그의 용도 |
| WO2016057367A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
| JP2017532342A (ja) * | 2014-10-17 | 2017-11-02 | アムジエン・インコーポレーテツド | 眼療法のためのアンジオポエチン−１及びアンジオポエチン−２を対象とする抗体 |
| AU2015345321A1 (en) * | 2014-11-10 | 2017-04-20 | F. Hoffmann-La Roche Ag | Anti-ANG2 antibodies and methods of use |
| ES2764111T3 (es) | 2014-12-03 | 2020-06-02 | Hoffmann La Roche | Anticuerpos multiespecíficos |
| SG10201906859PA (en) | 2015-01-28 | 2019-08-27 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for angiogenesis |
| CN108136001B (zh) | 2015-04-03 | 2022-07-29 | 佐马技术有限公司 | 使用TGF-β抑制剂和PD-1抑制剂治疗癌症 |
| WO2017030909A1 (en) | 2015-08-14 | 2017-02-23 | Allergan, Inc. | Heavy chain only antibodies to pdgf |
| SG10201911226QA (en) | 2015-09-23 | 2020-01-30 | Genentech Inc | Optimized variants of anti-vegf antibodies |
| JP2019505565A (ja) | 2015-11-30 | 2019-02-28 | ピエリス オーストラリア プロプライエタリー リミテッド | 新規の抗血管新生融合ポリペプチド |
| WO2018114728A1 (en) | 2016-12-20 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy with a bispecific anti-ang2/vegf antibody and a bispecific anti-her2 antibody |
| KR102143132B1 (ko) * | 2016-12-26 | 2020-08-10 | 기초과학연구원 | 항 Ang2 항체를 포함하는 안구질환 예방 및 치료용 조성물 |
| SG11201908547VA (en) | 2017-03-22 | 2019-10-30 | Genentech Inc | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods |
| AR111249A1 (es) | 2017-03-22 | 2019-06-19 | Genentech Inc | Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares |
| JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
| KR102497171B1 (ko) | 2018-02-20 | 2023-02-08 | 기초과학연구원 | 항-안지오포이에틴-2(Ang2) 항체 및 그의 용도 |
| WO2019164219A1 (en) * | 2018-02-20 | 2019-08-29 | Institute For Basic Science | Anti-angiopoietin-2 antibodies and uses thereof |
| TW202027794A (zh) | 2018-10-03 | 2020-08-01 | 瑞士商諾華公司 | 血管生成素樣３多肽之持續遞送 |
| KR102527315B1 (ko) * | 2019-02-25 | 2023-05-03 | 주식회사 파멥신 | 항-Ang2 항체 및 이의 용도 |
| TW202115112A (zh) | 2019-06-27 | 2021-04-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗-angpt2抗體 |
| WO2021183849A1 (en) | 2020-03-13 | 2021-09-16 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| MX2022011752A (es) | 2020-03-24 | 2022-10-18 | Genentech Inc | Agentes de fijacion a tie2 y metodos de uso. |
| WO2021259200A1 (zh) * | 2020-06-22 | 2021-12-30 | 信达生物制药(苏州)有限公司 | 抗ang-2抗体及其用途 |
| AU2021360935A1 (en) | 2020-10-15 | 2023-05-25 | F. Hoffmann-La Roche Ag | Hyaluronic acid binding derivatives of versican (vg1) for long acting delivery of therapeutics |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5814464A (en) * | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
| US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| RU2277411C1 (ru) * | 2004-12-15 | 2006-06-10 | Ольга Алексеевна Кост | Фармацевтическая композиция для лечения глазных болезней, связанных с нарушением микроциркуляции и/или воспалительными процессами |
| CA2595610C (en) * | 2004-12-21 | 2013-03-05 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
| CA2799802A1 (en) * | 2004-12-21 | 2006-06-29 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
| WO2007014073A2 (en) * | 2005-07-22 | 2007-02-01 | Amgen Inc. | Concentrated protein lyophilates, methods, and uses |
| WO2007033216A2 (en) | 2005-09-12 | 2007-03-22 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state |
| NZ569787A (en) | 2005-12-15 | 2011-07-29 | Astrazeneca Ab | Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or FLT1 antagonist for treating cancer |
| AR059066A1 (es) | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| EP1987064A4 (en) * | 2006-02-01 | 2010-04-07 | Arana Therapeutics Ltd | DOMAIN ANTIBODY CONSTRUCT |
| US8507656B2 (en) * | 2008-01-28 | 2013-08-13 | Medimmune Limited | Stabilized angiopoietin-2 antibodies and uses thereof |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| US8133979B2 (en) * | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
| US8703132B2 (en) * | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| EP3495387B1 (en) * | 2012-07-13 | 2021-09-01 | Roche Glycart AG | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
-
2009
- 2009-12-11 US US12/635,825 patent/US8133979B2/en active Active
- 2009-12-14 MX MX2011005908A patent/MX2011005908A/es active IP Right Grant
- 2009-12-14 NZ NZ600005A patent/NZ600005A/xx unknown
- 2009-12-14 PE PE2011001109A patent/PE20120551A1/es active IP Right Grant
- 2009-12-14 EP EP09793471.5A patent/EP2379592B1/en active Active
- 2009-12-14 ES ES09793471.5T patent/ES2534635T3/es active Active
- 2009-12-14 JP JP2011539960A patent/JP5559191B2/ja active Active
- 2009-12-14 PE PE2013002135A patent/PE20140814A1/es active IP Right Grant
- 2009-12-14 HU HUE09793471A patent/HUE024545T2/hu unknown
- 2009-12-14 KR KR1020137023369A patent/KR101445518B1/ko active IP Right Grant
- 2009-12-14 KR KR1020117013735A patent/KR101381012B1/ko active IP Right Grant
- 2009-12-14 SI SI200931184T patent/SI2379592T1/sl unknown
- 2009-12-14 NZ NZ592856A patent/NZ592856A/en not_active IP Right Cessation
- 2009-12-14 RU RU2011129204/10A patent/RU2569107C2/ru not_active IP Right Cessation
- 2009-12-14 SG SG2011044344A patent/SG172216A1/en unknown
- 2009-12-14 MY MYPI2011002743A patent/MY155654A/en unknown
- 2009-12-14 WO PCT/EP2009/008930 patent/WO2010069532A1/en active Application Filing
- 2009-12-14 UA UAA201108713A patent/UA103912C2/uk unknown
- 2009-12-14 CA CA2744624A patent/CA2744624C/en not_active Expired - Fee Related
- 2009-12-14 RU RU2013140625/10A patent/RU2569461C2/ru active
- 2009-12-14 CN CN200980150647XA patent/CN102257008A/zh not_active Withdrawn
- 2009-12-14 AU AU2009328613A patent/AU2009328613B2/en not_active Ceased
- 2009-12-14 CA CA2916481A patent/CA2916481C/en active Active
- 2009-12-14 UA UAA201310603A patent/UA105151C2/uk unknown
- 2009-12-14 DK DK09793471T patent/DK2379592T3/en active
- 2009-12-14 CN CN201210237207.1A patent/CN102746400B/zh active Active
- 2009-12-14 PT PT97934715T patent/PT2379592E/pt unknown
- 2009-12-14 PL PL09793471T patent/PL2379592T3/pl unknown
- 2009-12-14 CN CN201410024638.9A patent/CN103739709B/zh active Active
- 2009-12-14 BR BRPI0923434A patent/BRPI0923434A2/pt not_active Application Discontinuation
- 2009-12-15 TW TW102107374A patent/TWI482631B/zh active
- 2009-12-15 TW TW098142952A patent/TWI396549B/zh not_active IP Right Cessation
- 2009-12-15 AR ARP090104876A patent/AR074756A1/es active IP Right Grant
-
2011
- 2011-05-19 IL IL213039A patent/IL213039A/en active IP Right Grant
- 2011-05-30 ZA ZA2011/03990A patent/ZA201103990B/en unknown
- 2011-05-31 CL CL2011001285A patent/CL2011001285A1/es unknown
- 2011-06-02 MA MA33908A patent/MA32876B1/fr unknown
- 2011-06-09 CR CR20110321A patent/CR20110321A/es unknown
- 2011-06-14 MY MYPI2013003828A patent/MY158438A/en unknown
- 2011-06-16 EC EC2011011139A patent/ECSP11011139A/es unknown
-
2012
- 2012-01-26 US US13/358,813 patent/US8361747B2/en active Active
- 2012-01-26 US US13/358,831 patent/US8399626B2/en active Active
- 2012-07-13 US US13/548,244 patent/US9109027B2/en active Active - Reinstated
- 2012-10-30 CL CL2012003054A patent/CL2012003054A1/es unknown
- 2012-12-04 US US13/693,085 patent/US9340609B2/en active Active
- 2012-12-18 HK HK12113037.4A patent/HK1172349A1/zh unknown
-
2013
- 2013-02-06 US US13/760,118 patent/US9073986B2/en active Active
- 2013-05-13 IL IL226350A patent/IL226350A/en active IP Right Grant
- 2013-08-28 CR CR20130418A patent/CR20130418A/es unknown
- 2013-08-30 JP JP2013179932A patent/JP5814317B2/ja active Active
- 2013-09-09 AR ARP130103201A patent/AR092487A2/es unknown
- 2013-09-30 ZA ZA2013/07297A patent/ZA201307297B/en unknown
- 2013-10-23 PH PH12013502192A patent/PH12013502192A1/en unknown
- 2013-10-25 EC ECSP13011139 patent/ECSP13011139A/es unknown
-
2014
- 2014-07-08 HK HK14106922.4A patent/HK1195775A1/zh unknown
-
2015
- 2015-04-22 HR HRP20150439TT patent/HRP20150439T1/hr unknown
- 2015-05-07 CY CY20151100399T patent/CY1116264T1/el unknown
- 2015-06-04 US US14/731,277 patent/US20150284457A1/en not_active Abandoned
-
2016
- 2016-04-12 US US15/097,097 patent/US20170029493A1/en not_active Abandoned
-
2018
- 2018-02-28 US US15/907,836 patent/US20180282404A1/en not_active Abandoned
-
2019
- 2019-09-26 US US16/583,839 patent/US20200262904A1/en not_active Abandoned
-
2021
- 2021-04-05 US US17/222,776 patent/US20210388071A1/en not_active Abandoned
-
2023
- 2023-03-31 US US18/193,889 patent/US20230227543A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20150439T1 (hr) | Protutijela za humani angiopoietin 2 | |
| HRP20160131T1 (hr) | Protutijela koja se vežu na izvanstaniäśnu domenu 4 od ljudskog csf1r i njihova uporaba | |
| AR123305A2 (es) | Proteínas de unión a antígeno | |
| HRP20201091T1 (hr) | Protutijela anti-axl | |
| PH12018502623A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| HRP20170568T1 (hr) | Protutijela anti-ox40 i postupci za njihovu uporabu | |
| HRP20171690T1 (hr) | Antitijela koja se vežu za humani cgrp receptor | |
| AU2016204274A1 (en) | Antibodies that bind to OX40 and their uses | |
| HRP20211444T1 (hr) | Anti-dll3 antitijelo | |
| HRP20170254T1 (hr) | Humanizirana i kimerna monoklonska protutijela usmjerena na cd47 | |
| HRP20140376T1 (hr) | Bispecifiäśna protutijela anti-vegf/anti-ang-2 | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| WO2016081746A8 (en) | Antibodies comprising modified heavy constant regions | |
| NZ595235A (en) | Compositions and methods for increasing muscle growth | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| JP2015503909A5 (hr) | ||
| NZ597996A (en) | Antibodies against human respiratory syncytial virus (rsv) and methods of use | |
| NZ625403A (en) | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| WO2007113172A3 (en) | Antibodies against amyloid-beta peptide | |
| EP2471817A3 (en) | Humanized antibody molecules specific for IL-31 | |
| JP2015522252A5 (hr) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| CO6260104A2 (es) | Anticuerpos contra la il-25 | |
| WO2009081285A3 (en) | Hepatitis c virus antibodies |